Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with Diabetic Nephropathy

Review of Diabetic Studies

Volumn 7, Issue 4, 2010, Pages 275-284

  Chiu, Cheng An ^a   Lu, Li Fen ^a   Yu, Teng Hung ^a   Hung, Wei Chin ^a   Chung, Fu Mei ^a   Tsai, I Ting ^a   Yang, Chih Ying ^a   Hsu, Chia Chang ^a   Lu, Yung Chuan ^a   Wang, Chao Ping ^a   Lee, Yau Jiunn ^b  

^a I SHOU UNIVERSITY   (Taiwan)

^b Lee's Endocrinologic Clinic   (Taiwan)

Author keywords

Coronary artery disease; Indoxyl sulphate; Renal function; Total p cresylsulphate; Type 2 diabetes

Indexed keywords

4 CRESYLSULPHATE; ADIPONECTIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOXYL SULPHATE; INSULIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SULFATE; UNCLASSIFIED DRUG; CRESOL; INDICAN; P CRESYLSULFATE; P-CRESYLSULFATE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENSINI SCORE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SCORING SYSTEM; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED;

CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CRESOLS; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INDICAN; MALE; MIDDLE AGED;

EID: 80055096092     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2010.7.275     Document Type: Article

References (47)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998. 339:229-234.
2. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract 2009. 83:220-226.
3. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009.13:534-539.
4. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005. 51:1535-1538.
5. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994. 124:96-104.
6. De Smet R, David F, Sandra P, Van Kaer J, Lesaffer G, Dhondt A, Lameire N, Vanholder R. A sensitive HPLC method for the quantification of free and total pcresol in patients with chronic renal failure. Clin Chim Acta 1998. 278:1-21.
7. Niwa T, Takeda N, Tatematsu A, Maeda K. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversedphase liquid chromatography. Clin Chem 1988. 34:2264-2267.
8. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005. 16:3430-3436.
9. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2010. In press.
10. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009. 54:891-901.
11. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, Miyazaki H. ROS and PDGF-beta receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 2009. 297:C389-C396.
12. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P. The uremic solute in-doxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007. 5:1302-1308.
13. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004. 65:442-451.
14. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, Yeh LR, Chen HJ, Lee YJ, Houng JY. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010. 211:579-583.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998. 15:539-553.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001. 285:2486-2497.
17. Gensini, GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983. 51:606.
18. Wang CP, Hsu HL, Hung WC, Yu TH, Chen YH, Chiu CA, Lu LF, Chung FM, Shin SJ, Lee YJ. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol 2009. 70:876-882.
19. Chung FM, Yang YH, Shieh TY, Shin SJ, Tsai JC, Lee YJ. Effect of alcohol consumption on estimated glomerular filtration rate and creatinine clearance rate. Nephrol Dial Transplant 2005. 20:1610-1616.
20. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS. P-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2010. In press.
21. Lee CT, Kuo CC, Chen YM, Hsu CY, Lee WC, Tsai YC, Ng HY, Kuo LC, Chiou TT, Yang YK, et al. Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis. Perit Dial Int 2010. 30:456-463.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.Ann Intern Med 1999. 130:461-470.
23. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001. 24:695-725.
24. Zerbini G, Gabellini D, Ruggieri D, Maestroni A. Dysfunction of cellular transporters and predisposition to diabetic nephropathy. Curr Diabetes Rev 2006. 2:163-168.
25. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med 2008. 8:533-543.
26. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005. 20:1048-1056.
27. Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens 2008. 17:560-565.
28. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005. 16:3430-3436.
29. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010. 25:1183-1191.
30. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009. 4:1551-1558.
31. Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. P-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009. 4:1932-1938.
32. Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, Takayama F, Aoyama I, Nakamura S, Endou H, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002. 13:1711-1720.
33. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. P-cresylsulphate, the main in vivo metabolite of pcresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007. 22:592-596.
34. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, Miyazaki H. ROS and PDGF-beta [corrected] receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 2009. 297:C389-C396.
35. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006. 69:1780-1785.
36. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974. 290:697-701.
37. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998. 9:S16-S23.
38. Gris JC, Branger B, Vecina F, al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994. 46:807-813.
39. Vanholder R, Van Laecke S, Glorieux G. The middlemolecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity? J Nephrol 2008. 21:146-160.
40. Chung FM, Tsai JC, Chang DM, Shin SJ, Lee YJ. Peripheral total and differential leukocyte count in diabetic nephropathy: The relationship of plasma leptin to leukocytosis. Diabetes Care 2005. 28:1710-1717.
41. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004. 44:1945-1956.
42. Piestrzeniewicz K, Luczak K, Goch JH. Value of blood adipose tissue hormones concentration--adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction. Neuro Endocrinol Let. 2008. 29:581-588.
43. Hung WC, Wang CP, Lu LF, Yu TH, Chiu CA, Chung FM, Chen HJ, Houng JY, Shin SJ, Lee YJ. Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 diabetic patients with coronary artery disease. Endocr J 2010. 57:793-802.
44. Bigalke B, Stellos K, Geisler T, Seizer P, Mozes V, Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets 2010. 21:11-19.
45. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007. 115:972-980.
46. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol 2009. 71:202-207.
47. Glorieux G, Cohen G, Jankowski J, Vanholder R. Platelet/leukocyte activation, inflammation, and uremia. Semin Dial 2009. 22:423-427.